Date: 2021 07 15

Date:_2021.07.15	
-	
Your Name:Wenxin Li	_
Manuscript Title: Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a	
patient harboring a BRCA2-inactivating mutation: a case report	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	

4	Consulting fees	_ √None			
5	Payment or honoraria for	√None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	,			
6	Payment for expert				
	testimony				
7	Support for attending meetings and/or travel				
8	Patents planned, issued or	√ None			
	pending	_ '			
	· •				
9	Participation on a Data	√ None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	√ None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√ None			
12	Receipt of equipment,	√ None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	√None			
	financial interests				
Plea	ise summarize the above co	nflict of interest in the fol	lowing box:		
Т	The author declares no conflict of interest.				
Plea	se place an "X" next to the	following statement to in	dicate your agreement:		

D-+-. 2021 07 1F

Date:_2021.07.15	_
Your Name: Zuohong Ma	
Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a <i>BRCA2</i> -inactivating mutation: a case report	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	

4	Consulting fees	_			
5	Payment or honoraria for	√None			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	√ None			
	testimony				
7	Support for attending meetings and/or travel	√None			
8	Patents planned, issued or	_			
	pending				
	Doublisiantian on a Doba				
9	Participation on a Data Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	√ None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√None			
12	Descint of a majora and	/			
12	Receipt of equipment, materials, drugs, medical	√None			
	writing, gifts or other				
	services				
13	Other financial or non-	√None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
T	The author declares no conflict of interest.				
Dia:	Diagonal and "Y" nove to the following statement to indicate your agreement:				
riea	Please place an "X" next to the following statement to indicate your agreement:				

Data: 2021 07 15

Date2021.07.15
Your Name:Xibo fu Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a <i>BRCA2</i> -inactivating mutation: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	

4	Consulting fees	_ √None			
5	Payment or honoraria for	√None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	√None			
	testimony				
7	Support for attending meetings and/or travel				
8	Patents planned, issued or	_ √None			
	pending				
9	Participation on a Data	_			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	√None			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid				
11	Stock or stock options	√None			
12	Descript of anythment	,			
12	Receipt of equipment,	_ √None			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	√ None			
13	financial interests				
Plea	ise summarize the above co	nflict of interest in the foll	owing box:		
T	he author declares no conflict o	of interest.			
Plea	ise place an "X" next to the	following statement to ind	icate your agreement:		

Date:_2021.07.15	
Your Name:Zhiqiang Hao	
Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic chapatient harboring a <i>BRCA2</i> -inactivating mutation: a case report	olangiocarcinoma in a
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	

4	Consulting fees	_ √None			
5	Payment or honoraria for	√None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	√None			
	testimony				
7	Support for attending meetings and/or travel				
8	Patents planned, issued or	_ √None			
	pending				
9	Participation on a Data	_			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	√None			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid				
11	Stock or stock options	√None			
12	Descript of anythment	,			
12	Receipt of equipment,	_ √None			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	√ None			
13	financial interests				
Plea	ise summarize the above co	nflict of interest in the foll	owing box:		
T	he author declares no conflict o	of interest.			
Plea	ise place an "X" next to the	following statement to ind	icate your agreement:		

Data: 2021 07 15

Date2021.07.15
 Your Name: Hai Shang
Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	

4	Consulting fees	_			
5	Payment or honoraria for	√None			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	√ None			
	testimony				
7	Support for attending meetings and/or travel	√None			
8	Patents planned, issued or	_			
	pending				
	Doublisiantian on a Doba				
9	Participation on a Data Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	√ None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	√None			
12	Descint of a majora and	/			
12	Receipt of equipment, materials, drugs, medical	√None			
	writing, gifts or other				
	services				
13	Other financial or non-	√None			
	financial interests				
Please summarize the above conflict of interest in the following box:					
T	The author declares no conflict of interest.				
Dia:	aco placo ap "Y" payt to the	iallawing statement to indicate	graamanti		
riea	Please place an "X" next to the following statement to indicate your agreement:				

Date:_2021.07.15

Your Name: Junping Shi
Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a
patient harboring a BRCA2-inactivating mutation: a case report
Manuscript number (if known):_ ATM-21-3681

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	_ √None	

4	Consulting fees	√ None	
	consulting rees	None	
5	Payment or honoraria for	√ None	
,	lectures, presentations,	√None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√ None	
	testimony		
	,		
7	Support for attending	√ None	
,	meetings and/or travel	^None	
	meetings and, or traver		
8	Patents planned, issued or	_	
	pending		
9	Participation on a Data		
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role		
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Receipt of equipment,		
	materials, drugs, medical		
	writing, gifts or other		
12	services	Charachai OriziMad Ca	
13	Other financial or non-	Shanghai OrigiMed Co.	
	financial interests	Ltd.	

Please summarize the above conflict of interest in the following box:

est to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:_2021.07.15	
Your Name:Mengping Lei	
Manuscript Title: Olaparib effectively treats local recurrence of extrahepatic cholangioc patient harboring a <i>BRCA2</i> -inactivating mutation: a case report	carcinoma in a
Manuscript number (if known):_ ATM-21-3681	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	_ √None	

4	Consulting fees	_ √None	
5	Payment or honoraria for	√None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending meetings and/or travel	√None	
8	Patents planned, issued or	_ √None	
	pending		
9	Participation on a Data	_ √None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	√ None	
11	Stock of Stock options	√None	
12	Receipt of equipment,	√ None	
12	materials, drugs, medical	_ vNone	
	writing, gifts or other		
	services		
13	Other financial or non-	Shanghai OrigiMed Co.	
	financial interests	Ltd.	
Plea	ise summarize the above co	nflict of interest in the follow	ving box:

Mengping Lei is from Shanghai OrigiMed Co. Ltd., The other authors have no conflicts of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Date:_2021.07.15	
Your Name: Mian Xu	
Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangi patient harboring a <i>BRCA2</i> -inactivating mutation: a case report	ocarcinoma in a
Manuscript number (if known):_ ATM-21-3681	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	_ √None	

4	Consulting fees	_	
-	Dayward and by the state of the		
5	Payment or honoraria for lectures, presentations,	√None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	√None	
	testimony		
7	Support for attending	√ None	
	meetings and/or travel	vNone	
_			
8	Patents planned, issued or pending	_ √None	
	pending		
9	Participation on a Data	√ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	√None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	√None	
12	Descipt of a military and		
12	Receipt of equipment, materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Shanghai OrigiMed Co.	
	financial interests	Ltd.	
Plea	ise summarize the above co	nflict of interest in the follow	ving hox.

Mian Xu is from Shanghai OrigiMed Co. Ltd., The other authors have no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:_2021.07.15
Your Name:Shili Ning Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	_ √None	

4	Consulting fees	_ √None		
5	Payment or honoraria for	√None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	√None		
	testimony			
7	Support for attending meetings and/or travel			
8	Patents planned, issued or	_ √None		
	pending			
9	Participation on a Data	_		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	√None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid			
11	Stock or stock options	√None		
12	Descript of anythment	,		
12	Receipt of equipment,	_ √None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	√ None		
13	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
T	The author declares no conflict of interest.			
Plea	Please place an "X" next to the following statement to indicate your agreement:			

D-+-. 2021 07 1F

Date:_2021.07.15	_
Your Name: Xiangdong Hua	
Manuscript Title:_ Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a <i>BRCA2</i> -inactivating mutation: a case report	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	√None	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	_ √None	

4	Consulting fees	_ √None		
5	Payment or honoraria for	√None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	√None		
	testimony			
7	Support for attending meetings and/or travel			
8	Patents planned, issued or	_ √None		
	pending			
9	Participation on a Data	_		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	√None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid			
11	Stock or stock options	√None		
12	Descript of anythment	,		
12	Receipt of equipment,	_ √None		
	materials, drugs, medical writing, gifts or other			
	services			
13	Other financial or non-	√ None		
13	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
T	The author declares no conflict of interest.			
Plea	Please place an "X" next to the following statement to indicate your agreement:			